ReviewJournal of clinical medicine2022
Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients-A Systematic Review and Meta-Analysis.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.JAMA network open · 2026Pooled it
- Aromatase enzyme: Paving the way for exploring aromatization for cardio-renal protection.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Pooled it
- The Ketogenic Diet as Adjunctive Strategy in Cancer Treatment-Therapeutic Benefits and Metabolic Risk Using Breast Cancer as an Example.Nutrients · 2026Review
- The Microbiota-Endometriosis Axis: An Immune-Endocrine Integration Model and Emerging Therapeutic Targets.International journal of molecular sciences · 2026Review
- Metabolic Syndrome Is Associated with Increased Plasma Fibroblast Growth Factor 21 (FGF21) in Postmenopausal Breast Cancer Survivors: Implications for Therapy and Diagnosis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Cardiovascular Implications of the Enhanced Games: Performance Enhancing Drugs in Competition and Recreation.Sports medicine - open · 2026Review
- New insights into sexual dimorphism in cardiometabolic health.Hormones (Athens, Greece) · 2026Review
- Cardiovascular Risks of Aromatase Inhibitors versus Tamoxifen in Postmenopausal Breast Cancer: A Multinational Cohort Study.Clinical epidemiology · 2026Article
- Cardiotoxicity in breast cancer patients treated with chemoradiotherapy.Exploration of targeted anti-tumor therapy · 2026Review
- Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study.Frontiers in oncology · 2026Article
- Nutritional Impact on Breast Cancer in Menopausal and Post-Menopausal Patients Treated with Aromatase Inhibitors.Cancers · 2025Review
- Decreased Sirtuin1 Protein and Aromatase Activity Index in Follicular Fluid is Correlated with Increased Germinal Vesicle Count in Polycystic Ovary Syndrome.Chonnam medical journal · 2025Article
- Trastuzumab therapy and new-onset hypertension in adolescents and young adults with breast cancer.Breast cancer research and treatment · 2025Article
- Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti-cancer agents.ESC heart failure · 2025Article
- Review
- Current Evidence on the Impact of Diet, Food, and Supplement Intake on Breast Cancer Health Outcomes in Patients Undergoing Endocrine Therapy.Nutrients · 2025Review
- Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System.Cancer medicine · 2025Article
- Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer.British journal of cancer · 2024Review
- Cardiovascular Disease With Hormone Therapy and Ovarian Suppression in Premenopausal Breast Cancer Survivors.JACC. CardioOncology · 2024Article
- Impact of a Physical Exercise and Health Education Program on Metabolic Syndrome and Quality of Life in Postmenopausal Breast Cancer Women Undergoing Adjuvant Treatment with Aromatase Inhibitors.Medicina (Kaunas, Lithuania) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Aromatase inhibitors (AIs) have been considered first-line therapy for patients with hormone-dependent breast cancer due to their high efficacy and good tolerability. However, AIs are not free of adverse events, and studies show that therapy with AIs is associated with an increased risk of cardiovascular events and the development of insulin resistance and diabetes. We searched the Cochrane Central Register of Controlled Trials, PubMed and EMBASE up to 27 October 2020 for the prevalence of cardiovascular and/or metabolic adverse effects during treatment with AIs in postmenopausal women with breast cancer. A meta-analysis was performed using a random effects model. Odds ratios and 95% confidence intervals were calculated and illustrated using forest plot charts. We performed separate analyses depending on trial design. Twenty two studies met the inclusion criteria. AIs were associated with a higher risk of cardiovascular events, especially when we compared study arms in which AIs were used (alone or in sequence with TAM) with the arms in which TAM was used alone (OR = 1.16; 95%CI 1.04-1.30) or when comparing patients taking AIs alone to patients taking TAM alone or in sequence with AIs (OR = 1.24; 95%CI 1.11-1.38). A pooled analysis of five trials comparing adjuvant AIs to TAM showed the odds for arterial hypertension being 1.31 times higher for patients taking AIs; however, this did not reach statistical significance (OR = 1.31; 95%CI 0.47-3.65). We have not shown an increased risk of dyslipidemia or weight gain with the use of AIs. Our results suggest that postmenopausal women with breast cancer treated with AIs have an increased risk of cardiovascular events in comparison with TAM, potentially due more to a cardioprotective effect of the latter than the cardiotoxicity of AIs. We were unable to prove a similar association for hypertension, dyslipidemia, hyperglycemia or weight gain. Further high-quality RCTs and post-marketing safety observational studies are needed to definitively evaluate the impact of AIs on metabolic disorders in breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.